Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma. - Centre Henri Becquerel Access content directly
Journal Articles Blood Year : 2024

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.

Nuria Martínez-Cibrian
  • Function : Author
Pau Abrisqueta
  • Function : Author
Manuel Guerreiro
  • Function : Author
Jose Maria Aspa-Cilleruelo
  • Function : Author
Krimo Bouabdallah
  • Function : Author

Abstract

In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.

Domains

Cancer
Embargoed file
Embargoed file
0 1 12
Year Month Jours
Avant la publication
Thursday, October 24, 2024
Embargoed file
Thursday, October 24, 2024
Please log in to request access to the document

Dates and versions

hal-04607118 , version 1 (15-07-2024)

Licence

Identifiers

Cite

Gilles Crochet, Gloria Iacoboni, Audrey Couturier, Emmanuel Bachy, Josu Iraola-Truchuelo, et al.. Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.. Blood, 2024, ⟨10.1182/blood.2024024526⟩. ⟨hal-04607118⟩
53 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More